(19)
(11) EP 4 081 197 A1

(12)

(43) Date of publication:
02.11.2022 Bulletin 2022/44

(21) Application number: 20907245.3

(22) Date of filing: 22.12.2020
(51) International Patent Classification (IPC): 
A61K 31/03(2006.01)
A61P 3/10(2006.01)
 A61K 31/13(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 3/10; A61K 31/13; A61K 45/06; A61K 31/137; A61K 31/135; A61K 31/275; A61K 31/138; A61K 31/27; A61K 31/421; A61K 31/4409; A61K 31/42; A61K 31/454; A61K 38/28; A61K 38/26; A61K 38/22; C12N 15/90; C12N 2740/16043
 
C-Sets:
  1. A61K 31/138, A61K 2300/00;
  2. A61K 31/27, A61K 2300/00;
  3. A61K 31/421, A61K 2300/00;
  4. A61K 31/4409, A61K 2300/00;
  5. A61K 31/42, A61K 2300/00;
  6. A61K 38/22, A61K 2300/00;
  7. A61K 38/26, A61K 2300/00;
  8. A61K 31/137, A61K 2300/00;
  9. A61K 38/28, A61K 2300/00;
  10. A61K 31/135, A61K 2300/00;
  11. A61K 31/454, A61K 2300/00;
  12. A61K 31/275, A61K 2300/00;
  13. A61K 31/13, A61K 2300/00;
(86) International application number:
PCT/US2020/066560
(87) International publication number:
WO 2021/133777 (01.07.2021 Gazette 2021/26)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 23.12.2019 US 201962952538 P

(71) Applicant: Joslin Diabetes Center, Inc.
Boston, MA 02215 (US)

(72) Inventors:
  • KISSLER, Stephan
    Boston, Massachusetts 02215 (US)
  • YI, Peng
    Boston, Massachusetts 02215 (US)

(74) Representative: Høiberg P/S 
Adelgade 12
1304 Copenhagen K
1304 Copenhagen K (DK)

   


(54) MONOAMINE OXIDASE INHIBITORS AS MODIFIERS OF BETA CELL VULNERABILITY IN TYPE 1 DIABETES